bob10
3rd February 2021, 10:24 AM
Vaccine vindication in Russia
A vaccine developed in Russia, known as Sputnik V, has exceeded expectations in a new study that showed it to have a 91.6 percent efficacy rate against the coronavirus (https://nl.nytimes.com/f/newsletter/6Ltl1JRNSMdmCHtpaViMKQ~~/AAAAAQA~/RgRh_Gh3P0TxaHR0cHM6Ly93d3cubnl0aW1lcy5jb20vMjAyMS 8wMi8wMi93b3JsZC9ldXJvcGUvcnVzc2lhLXZhY2NpbmUtc2Fm ZS1lZmZlY3RpdmUuaHRtbD9jYW1wYWlnbl9pZD0xNTQmZW1jPW VkaXRfY2JfMjAyMTAyMDImaW5zdGFuY2VfaWQ9MjY2ODgmbmw9 Y29yb25hdmlydXMtYnJpZWZpbmcmcmVnaV9pZD04NDUzNDY2OS ZzZWdtZW50X2lkPTUwODY1JnRlPTEmdXNlcl9pZD0zOGI2NTNm NTlkOGE3ODhkMmI4MDI5ZDM0OWZiMDVmMVcDbnl0QgpgEXfjGW DnJMk0Uhlyb2JlcnRsYWtlNDI5NDNAZ21haWwuY29tWAQAAAAA ) without serious side effects.
The peer-reviewed results in The Lancet, based on a clinical trial of 22,000 people, were a huge boost for the government of President Vladimir Putin, which faced international skepticism after approving and distributing the vaccine in August before late-stage trials had even begun.
“The development of the Sputnik V vaccine has been criticized for unseemly haste, corner cutting, and an absence of transparency,” wrote two British virology experts in the prestigious medical journal. “But the outcome reported here is clear and the scientific principle of vaccination is demonstrated.”
Doses of the Sputnik V vaccine are cheap, at about $20 for two shots, and they do not need to be kept at an ultracold temperature, leaving Russia well positioned to deliver a cheap vaccine at home and abroad.
The story ;
The Sputnik V Vaccine and Russia’s Race to Immunity | The New Yorker (https://www.newyorker.com/magazine/2021/02/08/the-sputnik-v-vaccine-and-russias-race-to-immunity?utm_source=nl&utm_brand=tny&utm_mailing=TNY_Daily_020221&utm_campaign=aud-dev&utm_medium=email&bxid=5cc9e26e3f92a477a0ea0693&cndid=52475003&hasha=38b653f59d8a788d2b8029d349fb05f1&hashb=acd4725d670d172aa9d05ce7f671dc63250efce1&hashc=c17365ab07572ed90614d245ada5ad675f6bc00189fa 766123c70d76d1d7cddf&esrc=bounceX&mbid=CRMNYR012019&utm_term=TNY_Daily)
A vaccine developed in Russia, known as Sputnik V, has exceeded expectations in a new study that showed it to have a 91.6 percent efficacy rate against the coronavirus (https://nl.nytimes.com/f/newsletter/6Ltl1JRNSMdmCHtpaViMKQ~~/AAAAAQA~/RgRh_Gh3P0TxaHR0cHM6Ly93d3cubnl0aW1lcy5jb20vMjAyMS 8wMi8wMi93b3JsZC9ldXJvcGUvcnVzc2lhLXZhY2NpbmUtc2Fm ZS1lZmZlY3RpdmUuaHRtbD9jYW1wYWlnbl9pZD0xNTQmZW1jPW VkaXRfY2JfMjAyMTAyMDImaW5zdGFuY2VfaWQ9MjY2ODgmbmw9 Y29yb25hdmlydXMtYnJpZWZpbmcmcmVnaV9pZD04NDUzNDY2OS ZzZWdtZW50X2lkPTUwODY1JnRlPTEmdXNlcl9pZD0zOGI2NTNm NTlkOGE3ODhkMmI4MDI5ZDM0OWZiMDVmMVcDbnl0QgpgEXfjGW DnJMk0Uhlyb2JlcnRsYWtlNDI5NDNAZ21haWwuY29tWAQAAAAA ) without serious side effects.
The peer-reviewed results in The Lancet, based on a clinical trial of 22,000 people, were a huge boost for the government of President Vladimir Putin, which faced international skepticism after approving and distributing the vaccine in August before late-stage trials had even begun.
“The development of the Sputnik V vaccine has been criticized for unseemly haste, corner cutting, and an absence of transparency,” wrote two British virology experts in the prestigious medical journal. “But the outcome reported here is clear and the scientific principle of vaccination is demonstrated.”
Doses of the Sputnik V vaccine are cheap, at about $20 for two shots, and they do not need to be kept at an ultracold temperature, leaving Russia well positioned to deliver a cheap vaccine at home and abroad.
The story ;
The Sputnik V Vaccine and Russia’s Race to Immunity | The New Yorker (https://www.newyorker.com/magazine/2021/02/08/the-sputnik-v-vaccine-and-russias-race-to-immunity?utm_source=nl&utm_brand=tny&utm_mailing=TNY_Daily_020221&utm_campaign=aud-dev&utm_medium=email&bxid=5cc9e26e3f92a477a0ea0693&cndid=52475003&hasha=38b653f59d8a788d2b8029d349fb05f1&hashb=acd4725d670d172aa9d05ce7f671dc63250efce1&hashc=c17365ab07572ed90614d245ada5ad675f6bc00189fa 766123c70d76d1d7cddf&esrc=bounceX&mbid=CRMNYR012019&utm_term=TNY_Daily)